Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report

In recent years, the introduction in the clinical setting of treatment combinations having immune checkpoint inhibitors as the backbone has dramatically improved the outcomes of patients suffering from advanced/metastatic renal cell carcinoma (RCC). Here we report the clinical course of a patient wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Napoli, Marilena, Pisano, Carmela, Setola, Sergio Venanzio, Perdonà, Sisto, Feroce, Florinda, Pignata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510992/
https://www.ncbi.nlm.nih.gov/pubmed/35765962
http://dx.doi.org/10.23750/abm.v93iS1.12876
Descripción
Sumario:In recent years, the introduction in the clinical setting of treatment combinations having immune checkpoint inhibitors as the backbone has dramatically improved the outcomes of patients suffering from advanced/metastatic renal cell carcinoma (RCC). Here we report the clinical course of a patient with a rapid and bulky bone recurrence of RCC after nephrectomy, experiencing a long-term benefit from the nivolumab–ipilimumab combination administered as first-line treatment. (www.actabiomedica.it)

Ejemplares similares